GlassScriptPhysician profile
Jessica Pratt
NPI 1851061915
$1,179.98
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.31 · 2022: $1,154.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.91 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $165.74 | 2022 | |
| Epi Health, LLC | $105.13 | 2022 | |
| Janssen Scientific Affairs, LLC | $102.31 | 2022 | |
| Novartis Pharmaceuticals Corporation | $90.78 | 2022 | |
| Sun Pharmaceutical Industries INC. | $72.21 | 2022 | |
| Lilly USA, LLC | $55.99 | 2022 | |
| Genzyme Corporation | $47.64 | 2022 | |
| Mayne Pharma Commercial LLC | $41.34 | 2022 | |
| Ucb, INC. | $34.93 | 2021-2022 | |
| Almirall LLC | $30.84 | 2021-2022 | |
| Leo Pharma INC. | $25.38 | 2022 | |
| Genentech USA, INC. | $23.56 | 2022 | |
| Incyte Corporation | $20.53 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.22 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.13 | 2022 | |
| Phadia US INC. | $17.47 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.87 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.